Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma

Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma

The impact of daratumumab on CD34+ hematopoietic stem cell (HSC) mobilization has recently been a matter of concern. To address this issue, we compared CD34+ HSC-related outcomes in patients with multiple myeloma treated with daratumumab-based quadruplets (N = 44) and bortezomib/thalidomide/dexameth...

Full description

Bibliographic Details
Main Authors: Flavia Bigi, Paola Tacchetti, Alessandro Giorgi, Gaia Mazzocchetti, Vincenza Solli, Simona Barbato, Barbara Sinigaglia, Elena Campanini, Emanuele Favero, Marco Talarico, Michele Puppi, Ilaria Rizzello, Serena Rocchi, Katia Mancuso, Lucia Pantani, Michele Cavo, Elena Zamagni
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Hematology
Subjects:
multiple myeloma
mobilization
hematopoietic stem cell (HSC)
daratumumab
plerixafor
Online Access:https://www.frontiersin.org/articles/10.3389/frhem.2024.1386973/full

Internet

https://www.frontiersin.org/articles/10.3389/frhem.2024.1386973/full

Similar Items